Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy of patients with androgen-independent prostate carcinoma using NY-ESO-1/LAGE1 peptide vaccine (SPORE: 11-01-30-14).

Next Previous
Trial Profile

Immunotherapy of patients with androgen-independent prostate carcinoma using NY-ESO-1/LAGE1 peptide vaccine (SPORE: 11-01-30-14).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccine NY-ESO-1 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 06 Nov 2012 Biomarkers information updated
  • 17 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
  • 17 Jan 2012 Actual patient number is 14 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top